anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A first data task station which has a first predetermined data content requirement. A data content receiver receives data content. A first activator enables the data content receiver through a data intake of data task station, to associate with a first data content. Movement of the first data content to an automator site of the first data task station, actuates the screener. A second activator of the computer, by operation of the automator, enables, after the first pre-determined data content satisfies the screen against said first pre-determined data content requirement, a second data task station associated with a second predetermined data content requirement. A disabler, by operation of the automator, after the first pre-determined data content satisfies the screen against the first pre-determined data content requirement, disables the further screen of the first data content of said first data station.
Ecopipam hydrochloride (HCl) is an investigational drug being studied for several possible diseases. To date, all clinical studies have been done using the ecopipam immediate release (IR) tablet. However, a controlled release (CR) capsule formulation of ecopipam has been produced that may be able to improve its effectiveness and reduce its side effects. The main purpose of this study is to evaluate the safety and tolerability of ecopipam CR capsules when given as single oral dose in healthy volunteers. Another purpose of the study is to measure how much CR and IR ecopipam gets into the blood stream, and how long the body takes to get rid of them. Information about any side effects that may occur will be collected.
Participants in the money management condition start the 4-week money management program immediately after randomization and complete the post-intervention assessment right after they finish the treatment. They will be invited to participate in an interview after completing the post-intervention assessment.
There is a marked diurnal fluctuation in the occurrence of acute myocardial infarction and sudden death, with peak incidences occurring in the early morning. Platelet aggregation has also been shown to increase in the early morning. The investigators will test the hypothesis that alpha 2a-adrenergic receptor (ADRA2A) genetic variation, specifically haplotype 4, affects platelet aggregation. The investigators will compare diurnal platelet aggregation in haplotype 4 subjects with subjects in the other haplotype families. In addition, the investigators will compare platelet aggregation after the cold pressor test in haplotype 4 with the other haplotype families. If there are no differences among haplotypes, then the haplotypes will be combined to analyze.
Occurring in 20% to 50% of patients, postoperative new-onset atrial fibrillation (AF) is the most common complication of coronary artery bypass graft (CABG) surgery. Reports have indicated that the occurrence of postoperative AF is associated with a prolonged stay in the hospital, readmission to the intensive care unit, stroke, and, consequently, increased overall costs. Moreover, recent results from both retrospective and prospective observational studies suggest that its associated early and late mortality risk is high. During the past decade, off-pump coronary bypass (OPCAB) surgery has gained widespread acceptance as an alternative to conventional on-pump CABG surgery, as avoiding cardiopulmonary bypass and myocardial ischemia-reperfusion is thought to significantly reduce postoperative systemic complications. Nevertheless, recent studies have revealed that OPCAB surgery does not reduce the incidence of postoperative AF, possibly because the consistent inflammatory differences between on-pump CABG and OPCAB surgery are present only at the beginning of the postoperative course, or partially because general surgical trauma may play a greater role. It has thus been anticipated that, as with on-pump CABG surgery, OPCAB surgery has high AF-related mortality and morbidity risks, and the prevention of new-onset AF following OPCAB surgery should significantly reduce the risk of these outcomes. To date, most reviews reflect a growing consensus in favor of the prophylactic administration of β blockers. In addition, the American College of Cardiology/American Heart Association guidelines for CABG surgery recommend β blockers for the prevention of AF. To the best of our knowledge, however, no prospective study has evaluated the merits of a specific β-blocking agent or concluded that each of these agents is equally efficacious.

Carvedilol, a non-selective beta adrenergic blocking agent approved for use in heart failure cases, has a number of ancillary activities including anti-inflammatory and antioxidant properties. Although the exact pathophysiology of new-onset AF following OPCAB surgery has not yet been elucidated, recent reports suggest that markers of inflammation and oxidative injury are elevated in patients with non-surgical AF. In addition, clinical studies indicate that, unlike the β1-selective agent metoprolol, carvedilol has incremental benefits for AF management in heart failure patients. The anti-inflammatory and antioxidant properties of carvedilol have generated interest in its use as a prophylaxis for postoperative AF.

These considerations led to the organization of COMPACT, a multi-center, randomized controlled trial of 650 patients designed to test the hypothesis that carvedilol is more effective than metoprolol, a conventional β1-selective antagonist, in suppressing new-onset AF following OPCAB surgery.
Doxorubicin (Dox) is extensively used as an antitumor agent, but its severe cardiotoxicity significantly limits its clinical use. Current treatments for Dox-induced cardiotoxicity are inadequate, necessitating alternative solutions. This study evaluated the effects of sarmentosin, a compound from Sedum sarmentosum, on Dox-induced cardiotoxicity and dysfunction. Sarmentosin was administered as a pretreatment to both mice and H9c2 cells before Dox exposure. Subsequently, markers of Dox-induced cardiotoxicity and ferroptosis in serum and cell supernatants were measured. Western blot analysis was utilized to detect levels of ferroptosis, oxidative stress, and autophagy proteins. Additionally, echocardiography, hematoxylin-eosin staining, ROS detection, and immunofluorescence techniques were employed to support our findings. Results demonstrated that sarmentosin significantly inhibited iron accumulation, lipid peroxidation, and oxidative stress, thereby reducing Dox-induced ferroptosis and cardiotoxicity in C57BL/6 mice and H9c2 cells. The mechanism involved the activation of autophagy and the Nrf2 signaling pathway. These findings suggest that sarmentosin may prevent Dox-induced cardiotoxicity by mitigating ferroptosis. The study underscores the potential of compounds like sarmentosin in treating Dox-induced cardiotoxicity.
This invention relates to a patch for the expulsion of insect poison from the skin after stings from membranous insects (Hymenoptera). The patch is characterized in comprising a poison-aspirating matrix comprising an expulsion agent as well as a swell layer, which swells after the addition of a liquid through a hole on the top of the patch and thus adds a light pressure to the poison-aspirating matrix towards the skin, whereby a local and relieving effect is achieved. In one embodiment, the matrix further comprises a local anesthetic. The expulsion agent is e.g. a carbohydrate. The swell layer consists e.g. of a silica gel.
The primary objective of this study is to assess whether malignant glioma patients receiving radiation therapy and concomitant TMZ are more satisfied with ondansetron or granisetron patch for the prevention of nausea and vomiting. The secondary objectives are 1) to compare the efficacy and compliance of granisetron patch and ondansetron in the prevention of nausea and vomiting during the 6 weeks of RT and concomitant TMZ, and 2) to assess the safety of the granisetron patch in preventing radiation induced nausea and vomiting in primary glioma patients receiving RT and TMZ.

All eligible subjects should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of temozolomide daily for a total of six weeks. Subjects will be randomized to receive one of two treatment sequences of antiemetic therapy for the prevention of nausea and vomiting associated with RT and concomitant TMZ. Sequence #1 involves administration of ondansetron for 3 weeks followed by the use of granisetron patch for 3 weeks; whereas sequence #2 involves the use of the granisetron patch for 3 weeks followed by 3 weeks of ondansetron. Toxicity will be assessed each week of radiation therapy based on the Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0. The subject will be asked to complete the modified MASCC Antiemesis Tool (MAT) questionnaire at baseline, and on days 2, 4, and 7 of each week of radiation therapy, as well as to record the use of all study medication and any antiemetic rescue medication taken daily. At the end of the weeks 3 \& 6, the subject will be asked to fill out a Treatment Satisfaction Questionnaire for Medication and will be asked at the end of week 6 to choose which antiemetic they prefer.
The present invention provides a system and method for operating medical devices. The system and method may be used to program an infusion pump. The system may be implemented in a variety of ways including as a computer program. When implemented as a computer program, the program includes logic for: accessing information related to the identity of a patient; accessing information regarding the identity of a medical treatment, the medical treatment having a treatment type; determining whether the medical treatment has been previously associated with the patient; providing a first error signal if the medical treatment has not been previously identified with the patient; accessing information related to the identity of a medical device, the medical device configured to administer the medical treatment type; determining whether a plurality of operating parameters for the medical device are consistent with the medical treatment, the operating parameters having been provided from a central computer, the operating parameters having been provided to the medical device without passing through a remote computer; providing a second error signal if the operating parameters for the medical device are not consistent with the medical treatment; enabling the medical device to provide the medical treatment to the patient; and verifying that the medical device is providing the medical treatment to the patient. Other systems, methods, features, and advantages of the present invention will be, or will become, apparent to one having ordinary skill in the art upon examination of the following drawings and detailed description. It is intended that all such additional systems, methods, features, and advantages included within this description, be within the scope of the present invention, and be protected by the accompanying claims. .
The invention belongs to the technical field of medicines, and particularly relates to a co-amorphous substance of free base or hydrochloride of pyrimidine derivative 1D228 and a dispersing agent, and a preparation method and application thereof. The present invention provides co-amorphous of the free base or hydrochloride salt of pyrimidine derivative 1D228 with a dispersant comprising polyvinylpyrrolidone or hydroxypropyl methylcellulose. After the free base of 1D228 and polyvinylpyrrolidone form co-amorphous, the solubility in water is increased, and the preparation and clinical use of the 1D228 preparation can be satisfied without salifying with acid. The 1D228 hydrochloride forms co-amorphous with polyvinylpyrrolidone, also increasing the solubility of 1D228 in water. In addition, the co-amorphous form of the free base or hydrochloride of the 1D228 and the dispersing agent provided by the invention has the characteristic of good stability, and the amorphous state conversion is not generated after long-term placement. Animal experiments in mice prove that the composition has excellent anti-tumor effect.
Non-diabetic volunteers with HbA1c \< 6.5%. Subjects will be treated with C18:0 supplementation or mock.
The use of 3-dimensional (3D) technology has become increasingly popular across different surgical specialities to improve surgical outcomes. 3D technology has the potential to be applied to robotic assisted radical prostatectomy to visualise the patient's prostate anatomy to be used as a preoperative and peri operative surgical guide. This literature review aims to analyse all relevant pre-existing research on this topic. Following PRISMA guidelines, a search was carried out on PubMed, Medline, and Scopus. A total of seven studies were included in this literature review; two of which used printed-3D models and the remaining five using virtual augmented reality (AR) 3D models. Results displayed variation with select studies presenting that the use of 3D models enhances surgical outcomes and reduces complications whilst others displayed conflicting evidence. The use of 3D modelling within surgery has potential to improve various areas. This includes the potential surgical outcomes, including complication rates, due to improved planning and education.
The invention aims to provide a traditional Chinese medicine granule decoction of a wild plant composition for radically treating and treating human stomach and intestinal diseases from the source. The traditional Chinese medicine composition is characterized in that the herba violae and the houttuynia cordata are used in the decoction to harmonize and promote wild plants to enter a human body to quickly dredge qi and blood of the stomach and intestines. Remove the dirt, garbage and harmful bacteria which seal the qi and blood of the stomach and the intestine. Can relieve stomach and intestine from distention, pain, heartburn, acid regurgitation, singultus, constipation, acute dilatation, intestinal obstruction, etc., and can block the occurrence of stomach and intestine hemorrhage, gastric ulcer, gastric erosion, gastric perforation, duodenal diseases and gastrointestinal cancer. The wild plant composition comprises wild cotton, herba Houttuyniae, wild buckwheat, radix et rhizoma Rhei preparata, herba Rostellulariae and wild vegetable seed. The invention has the characteristics of high treatment speed and obvious effect.
The study is a 7-session, double blind, placebo-controlled crossover study of the effects of tolcapone, the COMT inhibitor, on decision making and alcohol intake using a laboratory bar in moderate to heavy social alcohol drinkers. Subjects will be moderate to heavy social users of alcohol, defined as at least 10 standard drinks per week for women and at least 14 standard drinks per week for men. There will be one screening session followed by six additional visits including 2 laboratory bar sessions. On each study drug administration day, subjects will come in to the clinic for a medication dispensation visit and instructions on when and how to take the study drug for the remainder of the study. Study drug bottles will be equipped with MEMS caps to ensure compliance. After 5 days of drug administration, subjects will return to the clinic for a laboratory bar. This session will consist of administration of a standardized laboratory bar paradigm and a series of computerized and written decision-making tasks. Subjects will then be crossed over and complete the same series of study visits on the alternate study drug.
The invention discloses a compound and an application thereof in the aspect of Parkinson's disease. The compound, for short, is SAG and JK60. The ataxia caused by the Parkinson's disease is single-side rotation. The invention also includes the applications of the compound in a drug for treating, preventing or improving the ataxia caused by the Parkinson's disease. By means of delivery of the small-molecular compound SAG or JK60, it is hopeful for replacing DBS operation, and meanwhile, a treatment effect of quickly correcting the single-side rotation caused by the Parkinson's disease, which approximates or even is better than the DBS, can be achieved. Furthermore, a drug for treating the Parkinson's disease and other neurodegenerative diseases can be found, thereby achieving huge social benefit.
BACKGROUND Flavonifractor plautii belongs to the clostridium family, which can lead to local infections as well as the bloodstream infections. Flavonifractor plautii caused infection is rarely few in the clinic. To understand better Flavonifractor plautii, we investigated the drug sensitivity and perform genome sequencing of Flavonifractor plautii isolated from blood samples in China and explored the drug resistance and pathogenic mechanism of the bacteria. CASE REPORT The Epsilometer test method was used to detect the sensitivity of flavonoid bacteria to antimicrobial agents. PacBio sequencing technology was employed to sequence the whole genome of Flavonifractor plautii, and gene prediction and functional annotation were also analyzed. Flavonifractor plautii displayed sensitivity to most drugs but resistance to fluoroquinolones and tetracycline, potentially mediated by tet (W/N/W). The total genome size of Flavonifractor plautii was 4,573,303 bp, and the GC content was 59.78%. Genome prediction identified 4,506 open reading frames, including 9 ribosomal RNAs and 66 transfer RNAs. It was detected that the main virulence factor-coding genes of the bacteria were the capsule, polar flagella and FbpABC, which may be associated with bacterial movement, adhesion, and biofilm formation. CONCLUSIONS The results of whole-genome sequencing could provide relevant information about the drug resistance mechanism and pathogenic mechanism of bacteria and offer a basis for clinical diagnosis and treatment.
The cognition and attitude of menopausal women toward hormone replacement could have been changed since the report from WHI in July 2002. Previously, many women used hormone replacement to prevent cardiovascular disease and osteoporosis. Recently, the use has been challenged, exaggerated, and also discussed both in media press and academic meetings. Many women dare not to use them. The women who underwent hysterectomy and bilateral salpingo-oophorectomy before menopause may immediately face the problems caused by deficiency of female sex hormone. For this group of women, as yet there is no conclusion about whether the women should take hormone replacement therapy for a long time to osteoporosis, cardiovascular disease and other chronic disease. The arm for this study from WHI is not closed yet. While the women in our area might have been influenced by this report and have changed their mind. It is essential for us to make a clear understanding about the cognition and attitude for hormone replacement therapy for women who underwent hysterectomy and bilateral salpingo- oophorectomy. Therefore, it may be a pioneer study and worthwhile to do this study. Data from a medical center from 2000 to 2004 will be examined for evidence of bilateral oophorectomy \& hysterectomy. The cause for the surgery will be confirmed by pathological findings. These women who were under 50 years of age will be candidate of the study. The women will be interviewed about their beliefs, and cognition, regarding their quality of life and health risks as well as their opinion on menopause and hormone replacement therapy.
If assigned to the interdisciplinary group, participants will see social work, physical therapy, occupational therapy, speech therapy, and pharmacy in a scheduled rotation for about 45 minutes each. After these evaluations, the team meets with the participant's doctor for a discussion of treatment. After this meeting, the participants doctor will meet to discuss a treatment plan and make recommendations.
The invention discloses a traditional Chinese medicine combination of a rhizoma atractylodis macrocephalae honey paste agent and a preparation method. The traditional Chinese medicine combination is matched through 150-200g of raw rhizoma atractylodis macrocephalae, 70-100g of cortex pseudolaricis, 100-150g of fruit vinegar, and 120-150g of sophora flower honey. The preparation method comprises: grinding raw rhizoma atractylodis macrocephalae and cortex pseudolaricis into fine powder; sieving the fine powder through a sieve (the mesh of which is 80-120 mesh); putting the sieved fine powder together with fruit vinegar and sophora flower honey into a ceramic container while performing uniform stirring to obtain paste; and putting the paste into a glass container, and sealing the container for cold storage. The paste agent is used through uniform application to a tinea part once to twice per day. After application, the efficacy of clearing heat, dryness, and dampness, killing insects, and treating tinea of the skin is realized. Compared with the prior art, the traditional Chinese medicine combination is free of chemical components, is a non-antibiotic medicine, and is simple to manufacture and convenient to apply.
Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease characterized by the presence of multiple auto antibodies and is associated with a multisystemic illness. The clinical presentation of SLE ranges from mild to severe and the course of the disease is unpredictable, with periods of remission and flares. (1) Juvenile-onset systemic lupus erythematosus (jSLE) patients present more frequently in teenage years and accounts for 15%-20% of lupus population, and they typically have severe disease course than adult patients. A considerable number of jSLE patients have significant renal or central nervous system(CNS) involvement at the time of diagnosis.(1) It is slightly more common in girls, with a sex ratio about 4:3 before puberty; however after puberty, the sex difference increases to about 4:1.(2) The disease is more common in Native Americans,African Americans, and Asians. (3) Prevalence rate of jSLE have varied from 4-250 per 100,000 population.(4,5) JSLE is not rare in Egypt and Africa, representing an important subset that is commonly overlooked and requires special attention. (6,7) SLE ranges from an insidious, slowly progressive, chronic disease with exacerbations and remissions,to an acute and rapidly fatal disease. Constitutiona lfeatures such as fever, fatigue, anorexia, myalgia,weight loss are common both at onset and during exacerbations of the disease. (8,9) Familial Mediterranean fever (FMF), an autosomal recessively inherited autoinflammatory disorder, is characterized by recurrent, self-limited inflammatory attacks involving mainly serosal membranes. The disease has been associated with variations in the MEFV gene, which encodes the pyrin protein, in the great majority of patients.(10) FMF is the most common autoinflammatory disorder, and the rate of heterozygous carrier for MEFV gene variations is quite high in Eastern Mediterranean countries, including Turkey, Israel, and Armenia.(11,12) A higher acute phase response has been reported in asymptomatic heterozygous carriers, and heterozygosity for MEFV variations has been suggested to affect the course of other autoinflammatory disorders.(13,14) A connection between FMF and collagen diseases were suggested previously by multiple studies as that MEFV mutations M694V and M680I were observed to be associated with Behcet's Disease (BD), (15)Also the MEFV variants in exon 10 were suggested to affect the clinical presentation of Henoch-Schönleinpurpurain populations where FMF is common. (16) The mutation p.M694V/I in MEFV gene might be a risk factor for systemic onset juvenile idiopathic arthritis sJIA, (17)and M694V is accepted to be associated with more severe inflammation as compared to other mutations in patients with Polyarteritis nodosa.